Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients

Table 3

Bone mineral densities and vertebral fractures in patients with SM and MC alterations.

Patient	Diagnosis	LS; s	LS; s	FN; s	FN; s	TH; s	TH; s	Vertebral fracture	Treatment	Treatment efficacy (follow-up)
1	SM	-4.30		-2.80		-1.80		T6, T8, T9, T11, T12, L1, L3	Alendronate 70 mg/week	No incident fractures (12 months)
2	SM		n.a.		-1.50		-1.00	T6, L4, L5	Zoledronate 5 mg/12 months	No incident fractures (12 months)
3	SM	-4.20		-2.30		-2.40		T12	Alendronate 70 mg/week	No incident fractures (24 months)
4	MC alterations	-3.40		-2.50		-2.30		T7, T8, T9, L2, L3, L4	Teriparatide 20 mcg/day+denosumab 60 mg/25 weeks	No incident fractures and significant increases in BMDs ( months)
5	MC alterations	0.30		-1.60		-0.20		T11, T12	Treatment refused	Not available
6	MC alterations	-4.30		-2.80		-2.60		L2	Alendronate 70 mg/week	No incident fractures (12 months)
7	MC alterations		-3.90		-1.50		-1.30	T5, T6, T8, T10, T11, T12, L1, L2, L3, L5	Alendronate 70 mg/week	Not available (6 months)
8	PV	-2.8		-2.4		-1.7		No fracture detected	Risedronate 35 mg/week	Significant increases in BMDs (84 months)

Severe lumbar enthesophaties; SM: systemic mastocytosis; MC: mastocytosis; PV: polycythemia vera; LS s: lumbar spine -score; LS s: lumbar spine -score; FN s: femoral neck -score: FN s: femoral neck -score; TH s: total hip -score; TH s: total hip -score; n.a.: not assessed due to previous arthrodesis.